In recent years, therapeutics targeting molecules such as EGFR, HER-2, HER3, CLDN18.2, Mucin 1 have shown a degree of efficacy in managing progressive gastric cancer (Figure 2) (Table 2). This evidence concerns the gene EGFR and gastric cancer.